请思考什么原因?
表1 患者实验室检查动态结果
图1 HBV生命周期[3]
在第26届亚太肝病研究学会年会上,WHO提出要在2030年全面消灭病毒性肝炎的“2030目标”,值此第10届世界肝炎日到来之际,我们也希望能有更多肝病届同仁能够关注HBV再激活这一领域,共同努力改善高风险患者的再激活风险和预后。
[1] 中华医学会感染病学分会,中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版). 临床肝胆病杂志. 2019;35(1):2648-2669
[2] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Hepatol. 2017;67:246–254.
[3] Henry Lik-Yuen Chan, Alex Thompson, Michelle Martinot-Peignoux, et al. Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report. Journal of Hepatology. 2011;55:1121–1131
[4] 中国临床肿瘤学会,中华医学会血液学分会,中国医师协会肿瘤医师考核委员会等. 淋巴瘤免疫化疗乙型肝炎病毒再激活预防和治疗中国专家共识. 中国实用内科学杂志. 2014;34(1):32-39.
[5] Rohit Loomba, T Jake Liang. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies and future direction. Gastroenterology. 2017;152(6):1297–1309.
[6] Shigeru Kusumoto, Luca Arcaini, Xiaonan Hong, et al. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2019;133(2):137–146.
[7] Małgorzata Pawłowska, Robert Flisiak, Lidia Gil, et al. Prophylaxis of hepatitis B virus (HBV) infection reactivation – recommendations of the Working Group for prevention of HBV reactivation. Clin Exp Hepatol. 2019;5(3):195–202.
[8] Xiaofeng Liang, Shengli Bi, Weizhong Yang, et al. Epidemiological Serosurvey of Hepatitis B in China--declining HBV Prevalence Due to Hepatitis B Vaccination. Vaccine. 2009;27(47):6550-7.
联系客服